Steve Nissen's Take On The Saxagliptin Review
Executive Summary
Cleveland Clinic Cardiologist Steven Nissen had a lot to do with shaping the new guidance on cardiovascular safety for type 2 diabetes therapies. However, he was not asked to participate in the first real-world application of those guidelines to a pending drug (Bristol/AstraZeneca's saxagliptin). So we asked for his thoughts after the fact. Here is his response: